A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Doxorubicin (Primary) ; Ontorpacept (Primary)
- Indications Leiomyosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TTI-621-03
- Sponsors Pfizer
- 28 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 20 Sep 2023 Planned End Date changed from 5 Feb 2024 to 24 Dec 2023.
- 20 Sep 2023 Planned primary completion date changed from 5 Feb 2024 to 24 Dec 2023.